Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles.
OBJECTIVE
To describe the suppression of ovarian function with 0.02 mg ethinyl E(2)-2 mg chlormadinone acetate administered in a 24/4-day intake regimen in healthy women.


METHODS
Open, uncontrolled, multiple dosing, phase II trial.


METHODS
Single clinic.


METHODS
Forty women treated.


METHODS
Treatment for up to three cycles with 0.02 mg ethinyl E(2)-2 mg chlormadinone acetate given in a 24/4-day regimen.


METHODS
Assessments of ovarian function classified by the Hoogland and Skouby score, thickness of endometrium, cervical reaction, and sex hormone levels, as well as overall tolerability.


RESULTS
No ovulation was observed in the per protocol set (N=36), and one in the full analysis set (N=38) after vomiting and diarrhea. Absence of ovarian activity, residual ovarian activity, and formation of a luteinized unruptured follicle were observed in 75.0%, 15.9%, and 1.1% of medication cycles, respectively. Endometrial thickness was suppressed to 4 to 5 mm compared with 10 to 12 mm without medication. Cervical reaction was negative. Hormone levels were lower with medication than without, and the medication was well tolerated. Treatment-related adverse events were typical of those associated with hormonal contraceptive use.


CONCLUSIONS
Follicular development, cervical reaction, and endometrial thickness were suppressed profoundly after 0.02 mg ethinyl E(2)-2 mg chlormadinone acetate administration in a 24/4-day regimen, resulting in inhibition of ovulation and unfavorable conditions for fertilization, implantation, and thus pregnancy.
Spona
Jürgen
J
Vitalogic GmbH, Vienna, Austria. Electronic address: juergen.spona@vitalogic.at.
Binder
Natascha
N
Grünenthal GmbH, Aachen, Germany.
Höschen
Kornelia
K
Grünenthal GmbH, Aachen, Germany.
Feichtinger
Wilfried
W
Institute for Sterility Treatment, Vienna, Austria.
D000293:Adolescent; D000328:Adult; D000465:Algorithms; D002715:Chlormadinone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D004304:Dosage Forms; D004334:Drug Administration Schedule; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D034445:Ovulation Inhibition / Q000187:drug effects; D016896:Treatment Outcome; D055815:Young Adult
D003277:Contraceptives, Oral, Combined; D004304:Dosage Forms; D002715:Chlormadinone Acetate; D004997:Ethinyl Estradiol